Pazopanib in sarcomas
نویسندگان
چکیده
منابع مشابه
Pazopanib in the management of advanced soft tissue sarcomas
Therapy of soft tissue sarcomas represents an area of significant unmet need in oncology. Angiogenesis has been explored as a potential target both preclinically and clinically, with suggestions of activity. Pazopanib is a multitargeted tyrosine kinase inhibitor with prominent antiangiogenic effects. In a Phase II study, pazopanib demonstrated activity in strata enrolling patients with leiomyos...
متن کاملPazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
BACKGROUND Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy including anthracyclines. Data on the efficacy in vascular sarcomas are limited. The main objective of this study was to investigate the activity of pazopanib in vascular sarcomas...
متن کاملTherapeutic Efficacy and Dosage of Pazopanib for Metastatic or Unresectable Advanced Soft Tissue Sarcomas
Objective: The molecular targeted drug pazopanib is a selective oral tyrosine kinase inhibitor that exerts its effects on vascular endothelial growth factor receptors (VEGF-R) and inhibits angiogenesis. This study aimed to examine the therapeutic efficacy, incidence of adverse events (AEs), and dosage of pazopanib in Japanese patients with metastatic or unresectable advanced soft tissue sarcoma...
متن کاملPazopanib in renal cell carcinoma.
Pazopanib is an oral, multitargeted tyrosine kinase inhibitor that has been approved by the U.S. Food and Drug Administration for treatment of patients with advanced renal cell cancer on the basis of a randomized, double-blind, placebo-controlled, phase III trial, which showed that once a day dosing of 800 mg of pazopanib resulted in progression free survival of 9.2 months versus 4.2 months (P ...
متن کاملVOTRIENT (pazopanib) tablets Label
----------------------------INDICATIONS AND USAGE--------------------VOTRIENT is a kinase inhibitor indicated for the treatment of patients with: advanced renal cell carcinoma. (1) advanced soft tissue sarcoma who have received prior chemotherapy. (1) Limitations of Use: The efficacy of VOTRIENT for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Opinion in Oncology
سال: 2013
ISSN: 1040-8746
DOI: 10.1097/cco.0b013e3283622d3a